By Fineline Cube CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China’s National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.
Regulatory Overview
| Item | Detail |
|---|---|
| Sponsor | CSPC Pharmaceutical Group Limited (HKG: 1093) |
| Drug Candidate | Sirolimus (Albumin-Bound) for Injection |
| Classification | Class 2.2 new chemical drug (China NMPA) |
| Indication | Unresectable locally advanced or metastatic malignant PEComa |
| Regulatory Status | Marketing application accepted |
| Special Designations | Breakthrough Therapy Designation + Priority Review |
| Acceptance Date | 27 Jul 2026 |
Drug Profile & Mechanism of Action
- Active Ingredient: Sirolimus (rapamycin)
- Formulation Innovation: Albumin-bound delivery system (enhanced tumor targeting and pharmacokinetics)
- Drug Class: Macrolide immunosuppressant
- Primary Target: Mammalian target of rapamycin (mTOR) pathway
- Mechanism:
- Binds to immunophilin FKBP12 to form immunosuppressive complex
- Blocks mTOR pathway activation
- Inhibits cytokine-mediated T-lymphocyte activation and proliferation
- Arrests cell cycle transition from G1 to S phase
- Downregulates antibody production
- Therapeutic Rationale: PEComa tumors frequently exhibit mTOR pathway dysregulation, making them highly susceptible to mTOR inhibition
Clinical Context – Malignant PEComa
| Parameter | Clinical Significance |
|---|---|
| Disease Rarity | Ultra-rare soft tissue sarcoma (<1% of all sarcomas) |
| Treatment Challenges | Often unresectable at diagnosis; limited systemic therapy options |
| Current Standard | No approved therapies specifically for PEComa in China |
| mTOR Relevance | High frequency of TSC1/TSC2 mutations leading to mTOR hyperactivation |
| Unmet Need | Critical requirement for targeted therapies addressing molecular drivers |
The Breakthrough Therapy Designation reflects both the rarity of PEComa and the compelling rationale for mTOR inhibition in this molecularly defined patient population.
Market Impact & Strategic Implications
- Orphan Oncology Opportunity: Addresses ultra-rare indication with premium pricing potential and limited competition
- Regulatory Acceleration: Priority Review and Breakthrough Therapy Designation could reduce approval timeline by 6-12 months compared to standard review
- Formulation Innovation: Albumin-bound technology may provide superior efficacy and tolerability compared to conventional sirolimus formulations
- mTOR Franchise Expansion: Builds on established clinical validation of mTOR inhibitors in oncology while addressing unmet need in rare tumors
- China Leadership: Positions CSPC as pioneer in developing targeted therapies for ultra-rare cancers in China’s evolving orphan drug landscape
- Global Potential: Success in PEComa could support international regulatory filings and establish precedent for albumin-bound sirolimus in other mTOR-driven malignancies
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory pathways, approval timelines, and commercial potential for Sirolimus (Albumin-Bound). Actual results may differ due to risks including regulatory decisions, competitive dynamics, market acceptance, and post-marketing requirements.-Fineline Info & Tech